Vitamin c boost: could it make chemo safer for myeloma patients?
NCT ID NCT06313502
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial tests whether high-dose vitamin C, combined with a lower dose of the chemotherapy drug melphalan and a stem cell transplant, is safe and effective for people with relapsed multiple myeloma. The study enrolls 18 adults who have already tried at least three prior treatments. The goal is to see if the vitamin C can help the lower chemo dose work better while causing fewer side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
high-dose vitamin C (ascorbic acid) plus reduced-dose melphalan chemotherapy
What this could lead to
If it works, this could point toward a less toxic treatment option for relapsed multiple myeloma, using high-dose vitamin C to boost the effects of lower-dose chemotherapy.
What could go wrong
This is a very early Phase 1 trial with only 18 people, so it is too soon to know if it works or is safe. High-dose vitamin C can cause side effects like kidney stones or infusion reactions.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED/REFRACTORY MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of Arkansas for Medical Sciences
RECRUITINGLittle Rock, Arkansas, 72205, United States
Contact Phone: •••-•••-••••